{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21","upperLimit":"82","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"will be estimated for all patients using Kaplan-Meier methodology. This analysis will include all patients regardless of their transplantation status.","dispersionType":"95% Confidence Interval","groups":[{"description":"This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.\n\nBortezomib: Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m\\^2, days 1, 8, 15 and 22\n\nDexamethasone: Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).\n\nLenalidomide: Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression","id":"OG000","title":"Patients With Multiple Myeloma"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 7 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}